Table 2 Pretreatment characteristics of patients entering the immunotherapy limb of the study
M avium intracellulare REM malmoense REM xenopi REAll 3 species
M vaccaeNo M vaccaeM vaccaeNo M vaccaeM vaccaeNo M vaccaeM vaccaeNo M vaccae
Clari(n = 17)Cipro(n = 19)Clari(n = 19)Cipro(n = 18)Clari(n = 21)Cipro(n = 21)Clari(n = 22)Cipro(n = 20)Clari(n = 2)Cipro(n = 4)Clari(n = 4)Cipro(n = 3)Clari(n = 40)Cipro(n = 44)Clari(n = 45)Cipro(n = 41)
Sex (M/F)6/1113/69/1011/715/611/1012/1016/40/24/03/11/221/1928/1624/2128/13
Mean (SD) age (years)64.1 (13.2)63.8 (11.2)62.1 (9.9)66.3 (9.6)63.2 (9.5)59.9 (10.1)64.8 (11.3)66.4 (7.9)75.5 (6.4)72.0 (5.1)62.3 (6.4)61.7 (2.5)64.2 (11.2)62.7 (10.7)63.4 (10.4)66.0 (8.4)
BCG vaccination5 (29%)3 (16%)5 (26%)1 (6%)5 (24%)2 (10%)2 (9%)0 (0%)1 (50%)1 (25%)0 (0%)0 (0%)11 (28%)6 (14%)7 (16%)1 (2%)
Cavitation14 (82%)12 (63%)10 (53%)13 (72%)11 (52%)11 (52%)6 (27%)7 (35%)2 (100%)2 (50%)2 (50%)2 (67%)27 (68%)25 (57%)18 (40%)22 (54%)
⩾3 zones2 (12%)6 (32%)7 (37%)5 (28%)3 (14%)2 (10%)3 (14%)1 (5%)1 (50%)2 (50%)0 (0%)1 (33%)6 (15%)10 (23%)10 (22%)7 (17%)
Other pulmonary disease on chest radiograph8 (47%)10 (53%)9 (47%)10 (56%)9 (43%)9 (43%)6 (27%)7 (35%)1 (50%)3 (75%)4 (100%)2 (67%)18 (45%)22 (50%)19 (42%)19 (46%)
  • Cipro, ciprofloxacin; Clari, clarithromycin; E, ethambutol; R, rifampicin.